Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.~* The subject must have a radiologically measurable tumor~* The subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).~* Able to swallow and retain oral medication~* Sexually active subjects must use acceptable methods of contraception during the course of the study~* Adequate organ system function and blood counts~Exclusion Criteria:~* Prior treatment with a BRAF or a MEK inhibitor~* Prior systemic anti-cancer treatment for Stage IIIC (unresectable) or Stage IV (metastatic) melanoma. Prior systemic treatment in the adjuvant setting is allowed. (Note: Ipilimumab treatment must end at least 8 weeks prior to randomization.)~* The subject has received major surgery or certain tyes of cancer therapy with 21 days of starting treatment~* Current use of prohibited medication listed in the protocol~* Left ventricular ejection fraction less than the lower limit of normal~* Uncontrolled blood pressurl~* History or current evidence of retinal vein occlusion or central serous retinopathy~* Brain metastases unless previously treated with surgery or stereotactic radiosurgery and the disease has been stable for at least 12 weeks~* The subject is pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabrafenib + Trametinib (Type: EXPERIMENTAL): Dabrafenib and Trametinib combination
- Dabrafenib + Placebo (Type: ACTIVE_COMPARATOR): Dabrafenib and Trametinib placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).